Proteomics analysis of cerebrospinal fluid (CSF) from individuals with Alzheimer’s disease (AD) identified five subgroups with distinct underlying mechanisms and genetic risk profiles. These subtypes might be a step forward in realizing personalized treatment for AD.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022). A genome-wide association study in an AD sample that indicates the involvement of over 70 genetic loci in AD pathogenesis.
Johnson, E. C. B. et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat. Med. 26, 769–780 (2020). One of the first large-scale tissue proteomics studies indicating that alterations of several molecular processes are associated with AD pathology.
Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018). This paper presents the current research criteria for defining the presence of AD on the basis of biomarkers for Aβ and tau pathology.
Cosker, K. et al. Microglial signalling pathway deficits associated with the patient derived R47H TREM2 variants linked to AD indicate inability to activate inflammasome. Sci Rep. 11, 13316 (2021). This study found that microglia derived from induced pluripotent stem cells from patients harboring the TREM2R47H mutation had a reduced inflammasome response.
Tijms, B. M. et al. Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics. Brain 143, 3776–3792 (2020). A study that presented evidence for molecular subtypes in AD based on untargeted CSF proteomics.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Tijms, B. M. et al. Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles. Nat. Aging https://doi.org/10.1038/s43587-023-00550-7 (2024).
Rights and permissions
About this article
Cite this article
Protein levels in cerebrospinal fluid indicate different subtypes in Alzheimer’s disease. Nat Aging 4, 12–13 (2024). https://doi.org/10.1038/s43587-023-00563-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43587-023-00563-2
